CytoSorbents, Inc.

270 articles with CytoSorbents, Inc.

• CytoSorbents to Present at the Raymond James Life Sciences and MedTech Conference

  6/18/2019

  CytoSorbents Corporation, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the Raymond James Life Sciences and MedTech Conference in New York, NY. Both Dr. Chan and Chief Financial Officer Kathleen Bloch will meet with investors in 1x1 meetings throughout the day.

• CytoSorbents to Present at the Three Part Advisors 2019 East Coast IDEAS Investor Conference

  6/11/2019

  CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the Three Part Advisors 2019 East Coast IDEAS Investor Conference on Thursday, June 13, 2019 in Boston, MA. Dr. Chan will also meet with investors in 1x1 meetings throughout the day.

• CytoSorbents to Present at the Jefferies 2019 Global Healthcare Conference

  6/3/2019

  CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5, 2019 in New York, NY.

• CytoSorbents to Participate at the B. Riley FBR 20th Annual Institutional Investor Conference

  5/20/2019

  CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the B. Riley FBR 20th Annual Institutional Investor Conference on Wednesday, May 22, 2019 at 8:00AM PDT in Beverly Hills, CA.

• CytoSorbents Reports First Quarter 2019 Financial Results and Provides Second Quarter 2019 Guidance

  5/7/2019

  CytoSorbents Corporation, a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports financial and operational results for the quarter ending March 31, 2019.

• CytoSorbents to Report Q1 2019 Operating and Financial Results

  5/1/2019

  CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q1 2019 financial results after the market close on Tuesday, May 7, 2019.

• CytoSorbents Highlights the 6th International CytoSorb Users' Meeting and Recent Activities at the 2019 ISICEM and EuroELSO Conferences

  4/24/2019

  CytoSorbents Corporation shares highlights from the recent 6th International CytoSorb Users' Meeting and the Satellite Symposium at the 39th International Symposium on Intensive Care and Emergency Medicine in Brussels, Belgium, and the 8th Annual EuroELSO 2019 Conference held recently in Barcelona, Spain.

• CytoSorbents to Present at the H.C. Wainwright Global Life Sciences Conference 2019 London

  4/8/2019

  CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company to European investors, Monday, April 8, 2019, at the H.C. Wainwright Global Life Sciences Conference 2019 in London, England.

• Israel Approves CytoSorb Registration, CytoSorbents Announces Gad Medical as Distributor

  3/25/2019

  CytoSorbents Corporation announces that the Medical Device Division of the State of Israel Ministry of Health medical device regulation unit, has granted registration of CytoSorb in Israel, clearing the way to begin selling the device in the country.

• CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018

  3/7/2019

  2018 Total Revenue was $22.5 million, with 2018 Product Sales surpassing $20M for the first time, representing 51% growth over 2017

• CytoSorbents Expands Direct Sales to Poland, the Nordics, and the Netherlands

  3/5/2019

  CytoSorbents Corporation announced that it has expanded direct sales of CytoSorb for all applications to Poland and the Netherlands, and for critical care applications in Sweden, Denmark, and Norway.

• CytoSorbents to Report Fiscal 2018 Operating and Financial Results

  2/28/2019

  CytoSorbents Corporation, a critical care immunotherapy leader commercializing its blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report fiscal 2018 financial results on Thursday, March 7, 2019 at 4:45PM EST.

• CytoSorbents to Participate at the 8th Annual SVB Leerink Global Healthcare Conference

  2/25/2019

  CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will participate in a fireside chat to discuss the company at the 8th Annual SVB Leerink Global Healthcare Conference this Wednesday, February 27, 2019 at 10:00AM EST in New York City.

• CytoSorbents to Present at the 21st Annual BIO CEO & Investor Conference

  2/5/2019

  CytoSorbents Corporation announced that its Chief Executive Officer, Dr.

• CytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial

  2/4/2019

  CytoSorbents Corporation announced that the Data Safety Monitoring Board of the German government-funded REMOVE Endocarditis trial recommended continuation of the study following an interim analysis on the first 50 patients of the study.

• CytoSorbents Announces Expansion of CytoSorb® Partnership with Fresenius Medical Care

  1/22/2019

  Agreement brings innovative CytoSorb® therapy to Korea and Mexico and sets the stage for future growth   [22-January-2019]   MONMOUTH JUNCTION, N.J. , Jan. 22, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its  CytoSorb®  blood purification technology to treat deadly inflammation in critically-ill and ca

• CytoSorbents Issues Stockholder Letter with Preliminary 2018 Financial Results

  1/7/2019

  CytoSorbents achieved another year of record growth with total revenue of more than $22.3 million, including product sales of approximately $20.2 million, a 51% increase from a year ago   [07-January-2019]   MONMOUTH JUNCTION, N.J. , Jan. 7, 2019 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb

• CytoSorbents To Highlight Progress at Biotech Showcase 2019

  1/4/2019

  CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will provide a corporate update and highlight the company's progress at the Biotech Showcase 2019 conference on Monday, January 7, 2019 at 10:30 AM PST in San Francisco, California

• CytoSorbents to Present at the 30th Annual Piper Jaffray Healthcare Conference

  11/26/2018

  CytoSorbents Corporation will present an overview of the company at the 30th Annual Piper Jaffray Healthcare Conference in New York City on November 29, 2018. 

• CytoSorbents Recognized Again as One of the Fastest Growing Companies in North America on Deloitte's 2018 Technology Fast 500™

  11/19/2018

  Strong international demand for the Company's CytoSorb blood purification technology to control deadly inflammation drives 267% revenue growth over the past three years